Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tobemstomig Alone or With Tiragolumab vs Atezolizumab in Untreated Advanced Urothelial Cancer
NCT05645692Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Apr 2023
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 2 trial of tobemstomig, sponsored by Roche. Started Apr 2023; status: active, not recruiting.
02
Drugs
tobemstomig
Beyond the preview
Go deeper on NCT05645692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05645692.